ABBV Trading Analysis - 10/23/2026 03:13 PM — TRU-SENTIMENT

News Headlines & Context

The following context items are provided from general knowledge and are separated from the data-driven analysis below.

• AbbVie's recent ex-dividend date of October 15, 2026 (per embedded fundamentals) followed a quarterly dividend rate of $6.92, reflecting continued income-focused shareholder returns.
• Pipeline updates on immunology assets (Skyrizi, Rinvoq) and aesthetics (Botox) have remained a focal point for ABBV in 2026, with analysts monitoring post-Humira erosion stabilization.
• No major earnings catalyst is indicated before the next major options expiration of November 20, 2026, though fiscal year-end was December 2025 per fundamentals.
• Low beta of 0.11 suggests ABBV has been largely insulated from broad-market volatility relative to peers in the pharma sector.
• Context: Strong options-flow bullishness (84.6% call dollar volume) aligns with a stock near 52-week highs, but overbought RSI from data may temper headline-driven enthusiasm.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for ABBV (as of 2026-10-23):

• Trailing P/E is 81.20 and trailing EPS is $3.56, indicating a rich valuation relative to typical large-cap pharma peers; forward P/E, PEG ratio, and price-to-book are null (not provided).
• Dividend yield is 2.39% with a dividend rate of $6.92 and ex-dividend date of 2026-10-15; market cap is $504,352,862,970.00 with 1,767,117,000.00 shares outstanding.
• Beta is 0.11 (very low systemic risk); 52-week high is $291.40 and 52-week low is $190.75 (current price $284.37 is near the high).
• Institutional ownership is 52.91%; average volume is 5,063,000.00; historical volatility is 18.78%.
• Revenue growth, profit margins (gross/operating/net), ROE, debt-to-equity, and free cash flow are null in the data — cannot be assessed.
• Analyst consensus, target mean price, and number of opinions are null; no analyst target context available.
• Fundamentals show high valuation (P/E 81.20) but defensive characteristics (low beta, dividend). This diverges from the bullish options sentiment and overbought technicals (RSI 74.19) which imply momentum-driven positioning rather than fundamental re-rating.

Current Market Position

From the embedded data: Current price per indicators is $284.37 (calculated at 2026-10-23). Daily history shows 2026-10-22 close at $284.37 with intraday range $278.01–$285.76 and volume 3,887,207. Minute bars show 2026-10-23 14:30 bar with high $286.59 and close $285.82 on volume 2,369,184, then fading to $285.41 by 14:45.

Key levels from data: 30-day range high $291.40, low $253.92. Daily closes clustered $280–$288 in October. SMA 50 is $265.43; SMA 20 is $273.98; SMA 5 is $285.11. Bollinger upper $292.29, lower $255.67.

Intraday momentum: Opening 2026-10-22 at $284.57 dipped to $278.01 by 09:35 then recovered; 2026-10-23 ramp to $286.59 followed by narrowing range ($285.41–$285.69) indicates late-session consolidation.

Technical Analysis

SMA alignment: Price ($284.37) > SMA 5 ($285.11 slightly above is marginal) > SMA 20 ($273.98) > SMA 50 ($265.43) — bullish stack but SMA 5 is just above price, showing minor flattening. No bearish crossover.

RSI 74.19 is overbought (>70), signaling momentum extreme and potential pullback risk. MACD histogram +1.29 with MACD > signal confirms bullish momentum but no divergence cited. Bollinger Bands: price near upper third (upper $292.29), no squeeze (bands wide at $255.67–$292.29). 30-day range: price at $284.37 is 79.3% up the $253.92–$291.40 band, near top.

True Sentiment Analysis (Delta 40-60 Options)

Per True Sentiment options data (2026-10-23 15:12):

Call Dollar Volume: $2,120,415.00 (84.60%) Put Dollar Volume: $386,135.00 (15.40%) Total: $2,506,550.00

Sentiment is Bullish. Call contracts 1,116 vs put 276; call trades 40 vs put 23. Pure directional conviction (Delta 40-60 filter, 4.4% of total) shows strong call-side positioning. Near-term expectation: upward bias into Nov 20 expiry.

Divergence: Option spread recommendation notes "Divergence detected between technical indicators and options sentiment" — technicals show no clear direction per their detail, while sentiment is bullish. Data shows RSI overbought (contrarian caution) vs bullish flow.

Key Price Levels (Observational Only)